Skip to main
  1. Stocks
  2. Zenas Biopharma Inc
  3. Forecast
ZBIO

ZBIO Stock Forecast & Price Target

ZBIO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Zenas BioPharma is supported by a compelling obexelimab profile that combines flare prevention, a reversible non-depleting CD19/FcγRIIb mechanism, and meaningful steroid-sparing effects, including a week 52 glucocorticoid toxicity score improvement versus placebo of -11.4 (p=0.021). The INDIGO open-label extension also showed strong durability, with 12-month flare-free probabilities of 93% and 87%, while early vaccine data suggested preserved responsiveness in 6/7 influenza and 4/4 COVID-19 participants during a treatment-free window. Fundamentally, the stock appears attractive because IgG4-RD remains a chronic, relapsing disease with large unmet need, rising diagnosis, and a substantial commercial opportunity, while obexelimab’s at-home weekly dosing and differentiation from B-cell depleters could support adoption ahead of the May 27, 2027 PDUFA.

Bears say

Zenas BioPharma is a clinical-stage biopharmaceutical company whose outlook is pressured by heavy dependence on obexelimab, a lead asset that may fail to demonstrate efficacy, produce inconvenient dosing intervals, or trigger safety signals that could halt development. The company also faces meaningful regulatory risk, as delays could reduce market uptake and financing flexibility, while commercial competition from current and future therapies could further limit adoption. With management focused on a single reportable segment and no diversified revenue base cited, an inability to achieve sales estimates would leave the company highly exposed to clinical and commercialization setbacks.

ZBIO has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

ZBIO Analyst Forecast & Price Prediction

Get the latest ZBIO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZBIO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zenas Biopharma Inc (ZBIO) Forecast

Analysts have given ZBIO a Buy based on their latest research and market trends.

According to 6 analysts, ZBIO has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zenas Biopharma Inc (ZBIO)


ZBIO Analyst Forecast & Price Prediction

Get the latest ZBIO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZBIO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZBIO stock data and trends